Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2026)

Crinetics Pharmaceuticals has reported Other Non-Current Liabilities for 3 years, with the latest figure at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 178.78% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 178.78% YoY), and the FY2025 full-year result was $3.2 million, up 290.83% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.9 million, up from $3.2 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.9 million in Q1 2026, with the low at $202000.0 in Q2 2024.
• Average Other Non-Current Liabilities over 3 years is $2.1 million, with a median of $2.1 million recorded in 2025.
• Year-over-year, Other Non-Current Liabilities surged 1055.45% in 2025 and jumped 178.78% in 2026.
• Tracing CRNX's Other Non-Current Liabilities over 3 years: stood at $829000.0 in 2024, then jumped by 290.83% to $3.2 million in 2025, then soared by 52.04% to $4.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $3.2 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.

Peer Comparison